Get started
Author

R. Descourt

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study
2016 · Romain Corre, Laurent Greillier, et al. · Journal of Clinical Oncology · 405
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
2017 · Michaël Duruisseaux, Benjamin Besse, et al. · Oncotarget · 158
PDF
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
2017 · Nicolas Guibert, Fabrice Barlesi, et al. · Journal of Thoracic Oncology · 65
First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study
2020 · Karim Amrane, Margaux Geier, et al. · Cancer Medicine · 63
PDF
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial
2018 · Guy Meyer, Benjamin Besse, et al. · European Respiratory Journal · 55
PDF
A Mismatch Repair–Deficient Hepatoid Adenocarcinoma of the Lung Responding to Anti–PD-L1 Durvalumab Therapy Despite no PD-L1 Expression
2018 · Victor Basse, Ulrike Schick, et al. · Journal of Thoracic Oncology · 45
PDF
Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study
2021 · Philippe Thuillier, Claire Joly, et al. · Cancer Immunology Immunotherapy · 43
Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)
2018 · Romain Corre, Radj Gervais, et al. · Oncotarget · 32
PDF
Focus on treatment of lung carcinoid tumor
2013 · Elise Noel-Savina, Renaud Descourt · OncoTargets and Therapy · 32
PDF
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)
2019 · Renaud Descourt, Maurice Perol, et al. · Lung Cancer · 31
PDF
Three cases of immune cholangitis related to anti–programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer
2019 · Maxime Fouchard, Helene Jantzem, et al. · European Journal of Cancer · 31
Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort
2020 · Mateo Sanchis-Borja, Charles Ricordel, et al. · Lung Cancer · 30
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
2022 · Renaud Descourt, Laurent Greillier, et al. · Cancer Immunology Immunotherapy · 29
Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer
2016 · Gilles Quéré, Renaud Descourt, et al. · BMC Cancer · 27
PDF
Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer: The GFPC 05-03 Study
2010 · Renaud Descourt, Alain Vergnenegre, et al. · Journal of Thoracic Oncology · 27
Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort
2022 · Simon Baldacci, Benjamin Besse, et al. · European Journal of Cancer · 26
Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis
2019 · Elisabeth Gaye, Margaux Geier, et al. · Lung Cancer · 21
Recurrent venous thromboembolism under anticoagulant therapy: A high risk in adenocarcinoma?
2006 · Renaud Descourt, Grégoire Le Gal, et al. · Thrombosis and Haemostasis · 21
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study
2014 · J.B. Auliac, C. Chouaid, et al. · Lung Cancer · 20
ALK -rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
2015 · Florence Vergne, Gilles Quéré, et al. · Lung Cancer · 19
False Positive 18F-FDG Positron Emission Tomography Findings in Schwannoma—A Caution for Reporting Physicians
2018 · Paul Boré, Renaud Descourt, et al. · Frontiers in Medicine · 18
PDF
Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review
2018 · Hélène Babey, Gilles Quéré, et al. · Expert Review of Anticancer Therapy · 16
Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study
2022 · Geoffroy Bilger, Anne-Claire Toffart, et al. · Therapeutic Advances in Medical Oncology · 15
PDF
First-Line Pembrolizumab with or Without Platinum Doublet Chemotherapy in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%
2021 · Renaud Descourt, Christos Chouaid, et al. · Future Oncology · 15
Vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC): A Phase I dose-escalation study
2009 · J. Trédaniel, R. Descourt, et al. · Journal of Clinical Oncology · 14
Works count: 175
Citation count: 1,538
H-index: 19
I10-index: 32
Year
Topic
Type